Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7041 in Active Noninfectious Uveitis (Phase 1/2a)
2025-521713-57-00Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2 trial of REGN7041 in uveitis (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events. Started Mar 2026; status: completed.
02
Drugs
REGN7041
03
Conditions
uveitis
Beyond the preview
Go deeper on 2025-521713-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521713-57-00.